Get the Stockscreener App
0.6795
1.21%
0.0081
Vyne Therapeutics Inc stock is traded at $0.6795, with a volume of 122.18K.
It is up +1.21% in the last 24 hours and up +5.33% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.6714
Open:
$0.6798
24h Volume:
122.18K
Relative Volume:
0.63
Market Cap:
$22.66M
Revenue:
$570.00K
Net Income/Loss:
$-26.74M
P/E Ratio:
-1.0427
EPS:
-0.6517
Net Cash Flow:
$-33.12M
1W Performance:
-0.23%
1M Performance:
+5.33%
6M Performance:
+80.72%
1Y Performance:
-34.66%
1-Day Range:
$0.6601
$0.684
1-Week Range:
$0.66
$0.684
52-Week Range:
$0.2805
$1.96
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.6795 | 22.39M | 570.00K | -26.74M | -33.12M | -0.6517 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline - TipRanks
VYNE to Advance YB-101 into Phase 2 in Q2 2026; $200M Raised, Phase 2a Readout Expected H2 2027 - TradingView
Yarrow reverse merger refocuses VYNE (NASDAQ: VYNE) with $200M war chest - Stock Titan
VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04 - MSN
Nantahala (NASDAQ: VYNE) reports 2,000,000-share stake representing 6.00% - Stock Titan
Yarrow merger to refocus VYNE (NASDAQ: VYNE) with $200M financing - Stock Titan
MSN Money - MSN
VYNE Stock Price, Quote & Chart | VYNE THERAPEUTICS INC (NASDAQ:VYNE) - ChartMill
TradingKey - TradingKey
Vyne Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
VYNE Therapeutics (NASDAQ: VYNE) to become Yarrow Bioscience after merger - Stock Titan
VYNE Therapeutics Inc. (VYNE) beats Q4 2025 EPS expectations significantly, yet shares edge slightly lower in today's trading.Special Dividend - UBND thành phố Hải Phòng
VYNE Therapeutics Inc. (VYNE) reports narrower Q4 2025 loss than estimates, yet shares dip slightly in today’s trading.Post Announcement - Xã Vĩnh Công
VYNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VYNE Therapeutics (VYNE) Stock: Market Structure Shift (+3.21%) 2026-04-20Swing Entry Points - newser.com
Is VYNE Therapeutics (VYNE) stock suitable for new investors (Technical Weakness) 2026-04-18Sell Signals - UBND thành phố Hải Phòng
Death Cross: Is VYNE Therapeutics Inc a play on infrastructure spending2026 Movers & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Pulse: Can VYNE Therapeutics Inc expand its profit margins2026 Retail & Weekly High Return Forecasts - baoquankhu1.vn
Breakout Watch: Can VYNE Therapeutics Inc deliver consistent dividends2026 Big Picture & Real-Time Market Sentiment Reports - baoquankhu1.vn
Layoff Watch: Can VYNE Therapeutics Inc sustain earnings growthMarket Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
How does VYNE Therapeutics (VYNE) Stock react to Fed policy | Price at $0.61, Down 0.57%Crowd Breakout Signals - Newser
Weekly Earnings: Is VYNE Therapeutics Inc stock showing strong momentumWeekly Loss Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug PostEarnings: What analysts say about VYNE Therapeutics Inc stockEarnings Overview Report & Real-Time Market Trend Scan - baoquankhu1.vn
Is VYNE Therapeutics (VYNE) Stock exposed to global risks | Price at $0.61, Up 2.53%Smart Beta Flow - Newser
Published on: 2026-04-08 14:06:22 - baoquankhu1.vn
Rate Cut: What are analysts price targets for VYNE Therapeutics Inc2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
VYNE Stock Analysis: VYNE Therapeutics Inc. $0.6 Biotech Minor Dip Stock Review - Newser
VYNE (VYNE) CFO has 4,007 shares withheld to cover RSU taxes - Stock Titan
VYNE Therapeutics (VYNE) CSO covers taxes with 2,876 shares - Stock Titan
VYNE (VYNE) legal chief has 4,007 shares withheld to cover RSU taxes - Stock Titan
VYNE (NASDAQ: VYNE) CEO stock withheld to cover RSU tax bill - Stock Titan
Short Squeeze: Can VYNE Therapeutics Inc expand its profit marginsEarnings Risk Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger–VYNE, MASI, IBCP, and HCBN - Weekly Voice
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN - Benzinga
VYNE Therapeutics Stock: Merger with Yarrow Bioscience Reshapes Biotech Pipeline and Investor Landsc - AD HOC NEWS
Merger: VYNE (NASDAQ: VYNE) to combine with Yarrow; $100M financing pledged - stocktitan.net
Hedge Fund Bets: What is the long term forecast for VYNE Therapeutics Inc stockProfit Target & Real-Time Buy Signal Notifications - baoquankhu1.vn
Aug Mood: Can VYNE Therapeutics Inc expand its profit marginsPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Published on: 2026-03-27 08:05:47 - baoquankhu1.vn
ETF Watch: Does VYNE Therapeutics Inc stock have upside surprise potential2026 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
If You Invested $1,000 in Vyne Therapeutics Inc (VYNE) - Stock Titan
Setup Watch: What is the long term forecast for VYNE Therapeutics Inc stockEarnings Miss & Technical Confirmation Trade Alerts - baoquankhu1.vn
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):